Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics demonstrates strong potential as a clinical-stage biotechnology company, with early clinical data indicating significant improvements in regulatory T cell (Treg) function and biomarkers related to neurodegenerative diseases. The company's fiscal year 2025 showed a marked increase in collaboration revenue, rising to $7.9 million, primarily due to the successful acceptance of the Investigational New Drug (IND) application for COYA 302 in ALS, marking a decisive shift towards clinical execution. Additionally, ongoing advancements in clinical trials, including statistically significant results in Treg metrics, put Coya Therapeutics in a favorable position to provide ongoing updates that may reduce risks associated with its lead assets, bolstering investor confidence in its therapeutic pipeline.

Bears say

Coya Therapeutics Inc. reported a net loss of $21.2 million in 2025, an increase from $14.9 million in 2024, indicating worsening financial performance and rising operational costs. The company's key intellectual property may fail to adequately protect its products, posing a significant risk to its competitive positioning in the market. Additionally, potential patent interference proceedings and the evolving landscape of treatment methods for neurodegenerative, autoimmune, and metabolic diseases could further threaten the viability of Coya's therapies and contribute to future legal expenses.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.